Radical cystectomy in non-metastatic sarcomatoid bladder cancer: A direct comparison vs urothelial bladder cancer.

[1]  F. Saad,et al.  Survival trends in chemotherapy exposed metastatic bladder cancer patients and chemotherapy effect across different age, sex, and race/ethnicity. , 2022, Urologic oncology.

[2]  A. Masson-Lecomte,et al.  Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration , 2022, World Journal of Urology.

[3]  A. Masson-Lecomte,et al.  Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration. , 2021, European urology focus.

[4]  T. Tsuzuki,et al.  Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis , 2021, BJU international.

[5]  B. Baumann,et al.  Adjuvant and Neoadjuvant Radiation Therapy for Locally Advanced Bladder Cancer. , 2021, Clinical oncology (Royal College of Radiologists (Great Britain)).

[6]  F. Saad,et al.  Comparison Between Urothelial and Non-Urothelial Urethral Cancer , 2021, Frontiers in Oncology.

[7]  W. Sexton,et al.  Pathologic and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed with Cystectomy with or Without Neoadjuvant Chemotherapy. , 2020, The Journal of urology.

[8]  M. Babjuk,et al.  EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees. , 2019, European urology.

[9]  W. Oyen,et al.  EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  P. Dasgupta,et al.  The impact of non‐urothelial variant histology on oncological outcomes following radical cystectomy , 2019, BJU international.

[11]  Wei-Ting Hwang,et al.  Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial , 2017, JAMA surgery.

[12]  A. Briganti,et al.  Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study. , 2017, European urology focus.

[13]  S. Shariat,et al.  Characteristics and clinical significance of histological variants of bladder cancer , 2017, Nature Reviews Urology.

[14]  S. Shariat,et al.  Genetic determinants for chemo- and radiotherapy resistance in bladder cancer , 2017, Translational andrology and urology.

[15]  T. H. van der Kwast,et al.  Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  F. Montorsi,et al.  Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy. , 2017, Urologic oncology.

[17]  Wentao Bao.  Survival analysis in the presence of competing risks. , 2017, Annals of translational medicine.

[18]  A. Roychoudhury,et al.  Contemporary treatment patterns and outcomes of sarcomatoid bladder cancer , 2017, World Journal of Urology.

[19]  R. Trepeta,et al.  Sarcomatoid Carcinoma of the Urinary Bladder. , 2016, Clinical genitourinary cancer.

[20]  Holger Moch,et al.  The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. , 2016, European urology.

[21]  Liang Cheng,et al.  Contemporary bladder cancer: variant histology may be a significant driver of disease. , 2015, Urologic oncology.

[22]  David A. Green,et al.  Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. , 2013, European journal of cancer.

[23]  K. Stamatiou,et al.  Sarcomatoid Carcinoma of the Urinary Bladder: A Clinicopathological Study of 4 Cases and a Review of the Literature , 2010, Korean journal of urology.

[24]  F. Aversa,et al.  Regression modeling of competing risk using R: an in depth guide for clinicians , 2010, Bone Marrow Transplantation.

[25]  Chad A. LaGrange,et al.  Clinical Features of Sarcomatoid Carcinoma (Carcinosarcoma) of the Urinary Bladder: Analysis of 221 Cases , 2010, Sarcoma.

[26]  C. Dinney,et al.  Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. , 2007, The Journal of urology.

[27]  Marinus J C Eijkemans,et al.  Actual and actuarial probabilities of competing risks: apples and lemons. , 2007, The Annals of thoracic surgery.

[28]  J R Anderson,et al.  Analysis of survival by tumor response. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.